Aijun Shen
Overview
Explore the profile of Aijun Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wan Q, Xu Y, Jiang Y, Li J, Li Y, Ren X, et al.
Magn Reson Imaging
. 2025 Jan;
117:110332.
PMID: 39855368
Background: Preoperative prediction of clear cell renal cell carcinoma (ccRCC) grade can support optimal selection of surgical resection strategies. Currently, there is no effective preoperative method for accurately assessing the...
2.
Xu Y, Wan Q, Ren X, Jiang Y, Yao J, Wu P, et al.
Curr Med Imaging
. 2024 Apr;
20:e15734056284650.
PMID: 38591213
Background: To investigate the optimal B1,rms value of renal amide proton transfer-weighted (APTw) images and the reproducibility of this value, and to explore the utility of APT imaging of renal...
3.
Dang X, Li P, Shen A, Lu Y, Zhu Z, Zhang M, et al.
Cancer Med
. 2024 Mar;
13(6):e6991.
PMID: 38506226
Introduction: Chimeric antigen receptor (CAR) T cell therapy has markedly improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). The relative positioning of tumor lesions in lymphoma varies...
4.
Xu Y, Wan Q, Ren X, Jiang Y, Wang F, Yao J, et al.
Magn Reson Imaging
. 2023 Dec;
106:104-109.
PMID: 38135260
Objective: To investigate the potential of amide proton transfer-weighted (APTw) MRI in identifying benign and malignant renal tumors and to evaluate whether APTw MRI can add diagnostic value to diffusion-weighted...
5.
Shen A, Sun Y, Wang G, Meng X, Ren X, Wan Q, et al.
Adv Healthc Mater
. 2023 Sep;
12(31):e2300684.
PMID: 37714524
Multidrug resistance (MDR) is one of the major factors causing failure of non-small-cell lung cancer (NSCLC) chemotherapy. Real-time and accurate differentiation between drug-resistant and sensitive NSCLC is of primary importance...
6.
Wen X, Zhang M, Duan Z, Suo Y, Lu W, Jin R, et al.
J Med Chem
. 2023 Aug;
66(16):11118-11132.
PMID: 37552553
The DNA-encoded library (DEL) is a powerful hit-generation tool in drug discovery. This study describes a new DEL with a privileged scaffold quinazolin-4(3)-one developed by a robust DNA-compatible multicomponent reaction...
7.
Li D, Zhang Z, Li Y, Wang X, Zhong H, Yang H, et al.
J Med Chem
. 2023 May;
66(10):7016-7037.
PMID: 37184921
A novel series of benzamide derivatives were successively designed and synthesized prepared from the pyridazinone scaffold. Among them, ()-, demonstrated potent inhibitory activity toward human class I HDAC isoforms and...
8.
Li M, Tang J, Lin C, Shen A, Ma X, Wu J, et al.
Adv Healthc Mater
. 2023 May;
12(24):e2300602.
PMID: 37184883
Accurately evaluating tumor responses to immunotherapy is clinically relevant. However, non-invasive, real-time visualization techniques to evaluate tumor immunotherapy are still lacking. Herein, a smart responsive fluorescence-MR dual-modal nanoprobe, QM(GP)-MZF(CP), is...
9.
Chen J, He H, Wei A, Li Y, Cheng G, Qin H, et al.
Eur J Med Chem
. 2022 Apr;
236:114259.
PMID: 35395439
Novel pyrrolopyridone BET degraders were designed and synthesized based on the binding mode between the pyrrolopyridone BET inhibitor with the BRD4 protein. The potent degraders on MV-4-11 cells were discovered...
10.
Li M, Gao X, Lin C, Shen A, Luo J, Ji Q, et al.
J Nanobiotechnology
. 2021 Oct;
19(1):336.
PMID: 34689763
Macrophage cell membrane-camouflaged nanocarriers can effectively reduce immune cell clearance and actively target tumors. In this study, a macrophage cell membrane-camouflaged mesoporous silica nanorod (MSNR)-based antitumor drug carrier equipped with...